{"id":"NCT00617123","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Ocular Safety of SCH 530348 in Subjects Participating in the Schering-Plough P04737 Study (TRA^SM-Secondary Prevention Ocular Safety Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-07-01","primaryCompletion":"2010-10-01","completion":"2010-10-01","firstPosted":"2008-02-15","resultsPosted":"2014-07-14","lastUpdate":"2018-09-21"},"enrollment":258,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Atherosclerosis","Ischemia","Myocardial Infarction","Cerebrovascular Accident"],"interventions":[{"type":"DRUG","name":"Vorapaxar 2.5 mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Vorapaxar","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is designed to evaluate the long-term ocular safety of SCH 530348 (vorapaxar) in participants with established atherosclerotic disease who are enrolled into the TRA 2Â°P - TIMI 50 Study (P04737) (NCT00526474).","primaryOutcome":{"measure":"Number of Participants Who Develop Vacuolization in the Inner Nuclear Layer (INL) of the Retina as Measured by Ocular Coherence Tomography (OCT)","timeFrame":"Up to 12 months","effectByArm":[{"arm":"Vorapaxar","deltaMin":1,"sd":null},{"arm":"Placebo","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":0},"commonTop":[]}}